BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 32908883)

  • 1. Long-Term Effects of Half-Time Photodynamic Therapy on Retinal Sensitivity in Eyes with Chronic Central Serous Chorioretinopathy.
    Iwase T; Yokouchi H; Kitahashi M; Kubota-Taniai M; Baba T; Yamamoto S
    Biomed Res Int; 2020; 2020():3190136. PubMed ID: 32908883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results.
    Fujita K; Yuzawa M; Mori R
    Retina; 2011 Apr; 31(4):772-8. PubMed ID: 20890236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of integrity of cone outer segment tips line with retinal sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Shinoda K; Imamura Y; Matsumoto CS; Mizutani Y; Mizota A; Yuzawa M
    Am J Ophthalmol; 2012 Sep; 154(3):579-85. PubMed ID: 22818904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microperimetric changes and fixation stability status after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Gulkas S; Sahin O
    Eur J Ophthalmol; 2020 Sep; 30(5):1053-1060. PubMed ID: 31256613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group.
    Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M
    Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microperimetric changes after photodynamic therapy for central serous chorioretinopathy.
    Senturk F; Karacorlu M; Ozdemir H; Karacorlu SA; Uysal O
    Am J Ophthalmol; 2011 Feb; 151(2):303-9.e1. PubMed ID: 21168824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between redefined optical coherence tomography parameters and best-corrected visual acuity in non-resolving central serous chorioretinopathy treated with half-dose photodynamic therapy.
    van Rijssen TJ; Mohabati D; Dijkman G; Theelen T; de Jong EK; van Dijk EHC; Boon CJF
    PLoS One; 2018; 13(8):e0202549. PubMed ID: 30142176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y; Li L; Xu G; Wang W
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.
    Hagen S; Ansari-Shahrezaei S; Smretschnig E; Glittenberg C; Krebs I; Graf A; Binder S
    Graefes Arch Clin Exp Ophthalmol; 2013 Apr; 251(4):1081-9. PubMed ID: 22926253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.
    Atik A; Hu Y; Yu H; Yang C; Cai B; Tao Y; Li D; Chen Y; Lu L; Li G; Yuan L
    BMC Ophthalmol; 2017 Aug; 17(1):140. PubMed ID: 28797227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).
    Lai TY; Wong RL; Chan WM
    Trans Am Ophthalmol Soc; 2015; 113():T8. PubMed ID: 26755855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.
    Vasconcelos H; Marques I; Santos AR; Melo P; Pires I; Figueira J; de Abreu JF; Cachulo ML; Silva R
    Graefes Arch Clin Exp Ophthalmol; 2013 Jul; 251(7):1697-705. PubMed ID: 23389551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF; Espinoza JV
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinal sensitivity after selective retina therapy (SRT) on patients with central serous chorioretinopathy.
    Yasui A; Yamamoto M; Hirayama K; Shiraki K; Theisen-Kunde D; Brinkmann R; Miura Y; Kohno T
    Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):243-254. PubMed ID: 27497611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Early and Late Morphological and Functional Changes After Verteporfin Photodynamic Therapy.
    Iacono P; Tedeschi M; Boccassini B; Chiaravalloti A; Varano M; Parravano M
    Retina; 2019 May; 39(5):980-987. PubMed ID: 29346241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.